A Nicotine Pharmacokinetics and Smoking Behaviour Study Examining Cigarette Ingredients
NCT ID: NCT03272295
Last Updated: 2022-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2017-09-12
2017-12-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Randomised, Cross-Over, Nicotine Pharmacokinetic and Pharmacodynamic Study of Heated Tobacco Products Compared to Combustible Cigarettes
NCT05459857
Nicotine Pharmacokinetic Study of Heated Tobacco and Heated Herbal Products
NCT06093659
Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG
NCT05789420
A Relative Bioavailability Study of Nicotine Delivery From Selected Oral Nicotine Products
NCT05452278
Comparative Pharmacokinetic Study of New Oral Nicotine Replacement Therapy Products.
NCT01227720
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Reference product (product 1) x 2, Single ingredients products 2, 3, 4, 5, 6 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
Reference cigarette
The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.
Cigarette with carob bean extract
Based on reference cigarette with added ingredient
Cigarette with cocoa powder
Based on reference cigarette with added ingredient
Cigarette with fenugreek extract
Based on reference cigarette with added ingredient
Cigarette with fig juice
Based on reference cigarette with added ingredient
Cigarette with glycerol
Based on reference cigarette with added ingredient
Cigarette with multiple ingredients
Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
Arm B
Reference product (product 1), Single ingredients products 7, 8, 9, 10, 11 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
Reference cigarette
The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.
Cigarette with guaiacol
Based on reference cigarette with added ingredient
Cigarette with liquorice extract powder
Based on reference cigarette with added ingredient
Cigarette plus I-menthol
Based on reference cigarette with added ingredient
Cigarette with propylene glycol
Based on reference cigarette with added ingredient
Cigarette with sorbitol
Based on reference cigarette with added ingredient
Cigarette with multiple ingredients
Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Reference cigarette
The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.
Cigarette with carob bean extract
Based on reference cigarette with added ingredient
Cigarette with cocoa powder
Based on reference cigarette with added ingredient
Cigarette with fenugreek extract
Based on reference cigarette with added ingredient
Cigarette with fig juice
Based on reference cigarette with added ingredient
Cigarette with glycerol
Based on reference cigarette with added ingredient
Cigarette with guaiacol
Based on reference cigarette with added ingredient
Cigarette with liquorice extract powder
Based on reference cigarette with added ingredient
Cigarette plus I-menthol
Based on reference cigarette with added ingredient
Cigarette with propylene glycol
Based on reference cigarette with added ingredient
Cigarette with sorbitol
Based on reference cigarette with added ingredient
Cigarette with multiple ingredients
Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1.1. males or females 1.2. 21 to 55 years of age, inclusive, demonstrated by appropriate proof of identification.
2. Subjects will have a:
2.1. BMI of 18.5 to 30.0 kg/m2, inclusive 2.2. body weight exceeding 52 kg (males) or 45 kg (females)
3. Subjects will be in good health, as judged by the PI or the appropriately qualified designee based on:
3.1. medical history 3.2. physical examination 3.3. vital signs assessment 3.4. 12-lead ECG 3.5. clinical laboratory evaluations 3.6. lung function tests
4. Subjects will have given their written informed consent to participate in the study and will have agreed to abide by the study restrictions.
5. Subjects must demonstrate the ability to comprehend the informed consent form (ICF), be able to communicate well with the PI or the appropriately qualified designee, understand and comply with the requirements of the study, and be judged suitable for the study in the opinion of the PI or the appropriately qualified designee.
6. Subjects will be willing to refrain from consuming alcohol within 24 hours prior to Admission.
7. Subjects will be regular smokers of factory made, non-menthol cigarettes whose chosen brand is within the ISO tar bands 6 to 10 mg, inclusive and should not change their usual brand cigarette for the duration of the study.
8. Subjects will have smoked their chosen brand for a minimum of 6 months and will have smoked for at least 3 years prior to Screening, and will typically smoke at least 10 and a maximum of 30 CPD.
9. Subjects must have a urine cotinine level \>200 ng/mL and an ECO measurement of \>10 ppm at Screening.
10. Subjects will be willing to use the study products and smoke only the study products provided to them during clinical confinement and to abstain from smoking when required.
Exclusion Criteria
2. Female subjects of childbearing potential who do not agree to use a highly effective method of birth control in conjunction with male barrier method contraception (i.e., a condom with spermicide) from the time of signing the ICF until 5-7 days after Discharge.
3. Female subjects who are pregnant or breastfeeding. This will be confirmed at Screening and at each Admission. Any female subject who becomes pregnant during this study will be withdrawn.
4. Subjects who have donated:
4.1. ≥450 mL of blood within 90 days prior to Admission 4.2. plasma in the 7 days prior to Admission 4.3. platelets in the 6 weeks prior to Admission
5. Subjects who have an acute illness (e.g., upper respiratory tract infection, viral infection, etc.) requiring treatment within 4 weeks prior to Admission.
6. Subjects who have used any nicotine or tobacco product other than commercially manufactured non-menthol, filter cigarettes within 14 days of Screening.
7. Subjects who are self-reported non-inhalers (smokers who draw smoke from the cigarette into the mouth and throat but who do not inhale). Subjects who are determined as non-inhalers at Screening will be excluded.
8. Subjects who, prior to enrolment, are planning to quit smoking in the next 12 months of Screening. All subjects will be informed that they are free to quit smoking and withdraw from the study at any time. Any subject who decides to quit smoking will be directed to appropriate stop smoking services
9. Subjects who have a significant history of alcoholism or drug/chemical abuse within 24 months prior to Screening, as determined by the PI or the appropriately qualified designee.
10. Subjects who have a positive urine drugs of abuse or alcohol screen (confirmed by repeat) at Screening or Admission.
11. Subjects who:
11.1. have serum hepatitis 11.2. are carriers of the hepatitis B surface antigen (HBsAg) 11.3. are carriers of the hepatitis C antibody 11.4. have a positive result for the test for human immunodeficiency virus (HIV) antibodies.
12. Subjects who have used prescription or OTC bronchodilator medication (e.g., inhaled or oral β-adrenergic agonists) to treat a chronic condition within the 12 months prior to the first Admission (Visit 1) and throughout the study.
13. Subjects who have received any medications or substances (other than tobacco) which:
13.1. are known to be strong inducers or inhibitors of CYP enzymes within 14 days or 5 half-lives of the drug (whichever is longer) prior to the first Admission (Visit 1) and throughout the study.
14. Subjects who are planning to undergo significant lifestyle changes during the study e.g., big change in exercise levels.
15. Subjects who are unable to communicate effectively with the PI/study staff (i.e., language problem, poor mental development, or impaired cerebral function).
16. Subjects who are unwilling or unable to comply with the study requirements.
17. Employees, and immediate relatives, of the tobacco industry or the clinical site.
18. Subjects who are still participating in another clinical study (e.g., attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity) in the past 3 months prior to first Admission (Visit 1).
19. Subjects who have any clinically relevant abnormal findings on the physical examination, medical history, ECG, lung function tests (forced expiratory volume in 1 second/ forced vital capacity \[FEV1/FVC\]), or clinical laboratory panel, unless deemed not clinically significant by the PI or the appropriately qualified designee.
20. Subjects who have, or who have had a history of, any clinically significant neurological, gastrointestinal, renal (including urinary tract infection or nephrolithiasis), hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological or other major disorder that, in the opinion of the PI or the appropriately qualified designee, would jeopardise the safety of the subject or impact on the validity of the study results.
21. Subjects who have previously been diagnosed with any form of malignancy.
22. Subjects who have any clinically significant abnormal laboratory safety findings at Screening and prior to first product use, as determined by the PI or the appropriately qualified designee (1 repeat assessment is acceptable).
23. Subjects who have previously been randomised into or withdrawn from this study.
24. Subjects who, in the opinion of the PI or the appropriately qualified designee, should not participate in this study.
21 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philip Morris Products S.A.
INDUSTRY
Imperial Brands PLC
INDUSTRY
Japan Tobacco Inc.
INDUSTRY
Korea Ginseng Corporation
INDUSTRY
British American Tobacco (Investments) Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Johnston Stewart, MB
Role: PRINCIPAL_INVESTIGATOR
Celerion GB Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Celerion
Belfast, Northern Ireland, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA21208
Identifier Type: OTHER
Identifier Source: secondary_id
BAT1117009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.